Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Cancer drug shows potential in treating severe asthma

US researchers explore the effects of imatinib on reducing mast cell activity in poorly controlled asthma.

Micrograph of a mast cell

Source: CNRI / Science Photo Library

Mast cells can persist in the airway despite high doses of glucocorticoids.

Mast cells are associated with severe asthma and airway hyperresponsiveness and in some patients they persist in the airway despite high doses of glucocorticoids.

The tyrosine kinase inhibitor, imatinib, used to treat leukaemia, targets a receptor known as KIT that is critical to mast cell function. In a paper published in The New England Journal of Medicine[1] (online, 18 May 2017), researchers explored whether the drug might have an effect on mast cells in 62 patients with poorly controlled severe asthma.

At three and six months, the team found that patients randomly assigned to imatinib had a greater reduction from baseline in airway responsiveness compared with those who received placebo. Imatinib treatment was also associated with evidence of reduced mast cell activity.

The researchers say that the findings indicate that strategies to target the KIT receptor and decrease mast cell counts could therefore be an important approach in severe asthma.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2017.20202936

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.


Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Micrograph of a mast cell
  • Molecular structure of imatinib

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.